15701-83-4

Upstream product

• 3542-14-1 3,3-diphenylpropene 
• 947-91-1 Diphenylacetaldehyde 
• 101-81-5 Diphenylmethane 
• 4646-55-3 N,N-dimethyl-3,3-diphenylpropan-1-amine 
• 781-35-1 1,1-diphenylacetone 
• 33609-25-5 3-bromo-1,1-diphenylpropan-2-one 
• 53780-27-1 1,1-diphenyl-3-bromo-propan-2-ol 

Downstream Products

• 134456-51-2 (1S,3R)-1-Aminomethyl-3-benzhydryl-isochroman-5,6-diol; hydrochloride 
• 385802-02-8 2-benzhydrylmorpholine 
• 28192-99-6 3-dimethylamino-1,1-diphenyl-propan-2-ol 
• 862647-09-4 (2R)-2-benzhydryloxirane 
• 1332886-85-7 (2S,4R,5R)-2-benzhydryl-5-bromotetrahydro-2H-pyran-4-ol 
• 1357157-56-2 3-(allyloxy)-1,1-diphenylpropan-2-ol 

Relevant academic research and scientific papers

AZA-PYRIDONE COMPOUNDS AND USES THEREOF

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H- pyran-4-ol (D-142)

Triple monoamine reuptake inhibitors have been implicated in the development of a new generation of antidepressants with higher efficacy than the currently existing therapies. In this paper, we have developed an alternative efficient synthetic route for triple monoamine reuptake inhibitor D-142 in 18.5% overall yield in 11 steps starting from diphenylmethane. D-142 was developed by us recently. The key step of the present synthetic strategy is the preferential formation of a bromohydrin from olefin via a cis-bromonium intermediate, which introduced significant efficiency in the overall synthesis. Furthermore, we have developed an efficient way to recycle the optically active intermediate diol back to the desired chiral epoxide.

Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner

In our structure-activity relationship study on 3,6-disubstituted pyran derivatives, we have carried out asymmetric synthesis and biological characterization of trisubstituted (2S,4R,5R)-2-benzhydryl-5- benzylaminotetrahydropyran-4-ol and (3S,4R,6S)-6-ben

TRI-SUBSTITUED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES

Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti- depressants.